Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Marinus Pharma CS

(NASDAQ: MRNS)
Add to Portfolio
+0.02 (+1.50%)
as of Oct 18, 2019

Last 1.35
Change +0.02 (+1.50%)
Open 1.38
Prev. Close 1.33
Today's Range
1.30
1.39
52wk Range
0.77
6.27
Volume 1,034,700
Avg Volume 2,183,370
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
MRNS +1.50% +16.38% -77.12%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS -0.99
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 69,930
Weighted Alpha -37.40
Standard Deviation +0.22
Profit Margin N/A
Beta 2.89

Growth Rates

YTD -52.96%
1-Year -76.40%
3-Year +1.50%
5-Year -80.80%

Opinion

Sell Hold Buy

Recent Headlines

Marinus Phase 2 Clinical Data on Ganaxolone in RSE

GlobeNewswire via COMTEX - Thu Oct 17, 07:30AM EDT
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today anno(full story)
MRNS: 1.35 (+0.02)

Marinus Pharmaceuticals Announces Inducement Grants

GlobeNewswire via COMTEX - Fri Sep 27, 04:05PM EDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the(full story)
MRNS: 1.35 (+0.02)

Thinking about buying stock in Beyond Meat, Canopy

PR Newswire via COMTEX - Thu Sep 26, 09:31AM EDT
InvestorsObserver issues critical PriceWatch Alerts for BYND, CGC, MRNS, RAD, and XXII.(full story)
XXII: 2.06 (+0.06), CGC: 20.21 (-0.55), MRNS: 1.35 (+0.02), RAD: 8.92 (+0.05)

Marinus Pharmaceuticals Announces Positive Top-Line

GlobeNewswire via COMTEX - Thu Sep 26, 07:30AM EDT
All patients achieved the primary endpoint(full story)
MRNS: 1.35 (+0.02)